![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials
UK Pharma Company Scancell Selects COVID-19 Vaccine for Clinical Trials
![COVID-19](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-image.gif?t=1615503643&width=430)
UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial.
SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.
In October, Scancell signed a manufacturing deal for SN14 with Cobra Biologics, a Cognate BioServices subsidiary, ahead of a planned phase 1 trial in 2021. The company, along with partners University of Nottingham and Trent University, received a British government grant to support the study.
The vaccine “could have significant advantages over first-generation vaccines, either on its own or in combination with other vaccines to broaden and strengthen the immune response for long- term protection,” Scancell said.
Upcoming Events
-
18Jul
-
21Oct